DFX Intelligence
Venture Capital Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Venture Capital Intelligence at $199 a month for every name. Every figure, date and source on this page is public either way.
Firms / V•••••• C•••••• M••••••••• L••
V•••••• C•••••• M••••••••• L••
venture manager, reported GAV $586M across 4 vehicles
Importance
36
elevated
Active deployment
4
low
Emerging
0
low
Completeness
81
high
Freshness
98
high
Research priority
5
low
Identity and regulatory footprint
- Headquarters
- Edina, MNadviserinfo.sec.gov
- Office address
- 3601 W. 76TH ST, SUITE 20, Edina, MN, 55435adviserinfo.sec.gov
- Business phone
- (612) 217-8688adviserinfo.sec.gov
- Website
- v•••••••••.com
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 16, 2026
- Private funds reported
- 3 (3 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $984Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business phone
- (612) 217-8688adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
1 observed deals
Stated (the firm’s website)
- Sectors
- healthcare, biotech, medtech
- Stages
- series a, growth
- Geography
- washington, d.c
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- venture capital
Observed (from deals on record)
Stage at participation
series a 100%
Stage at first entry
series a 100%
Sectors
Biotechnology 100%
lead rate 100%follow-on rate 0%new logos, 12 months 1
Funds and vehicles
4 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| V•••••• C•••••• I•• L••• | Fund | 2022 adv first reported | Active deployment | $322M Mar 19, 2024 | 54 | $0 of $300M | Jul 14, 2021 |
| V•• F••• I• L••• | Fund | unknown | Unknown | $264M Mar 19, 2024 | 57 | unknown | unknown |
| V•••••• C•••••• I••• L••• | Fund | unknown | Unknown | unknown | unknown | $0 of $425M | Sep 27, 2024 |
| V•••••• C•••••• M••••••••• L•• | Fund | unknown | Unknown | unknown | unknown | $0 of $200M | Dec 10, 2018 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
45 current, 0 departed
A•••••• K•••
AssociateInvestment Professional
P•••• G•••••••
AssociateInvestment Professional
A•••• S••••
Founder or executiveCEO, Artelon
A••• B•••••
Founder or executiveCEO, Alleviant Medical
A•• T•••••
Founder or executiveCEO, Topera
B•• P••••••
Founder or executiveCEO, Sonex H•••••
B•••• S••••
Founder or executiveCEO, Vesper Medical
D••••• W•••
Founder or executiveCEO, Nuvaira
E••• F•••••
Founder or executiveCEO Nalu Medical
G••• d• J•••
Founder or executiveVice Chairman/Founder, ForSight Labs
J•••• M••
Founder or executiveCEO, Cleerly H•••••
J•• B••••••
Founder or executiveCEO, Atritech
K•••• H••••
Founder or executiveCEO, CVRx
L••••• T••••
Founder or executiveCEO, Outset Medical
M•••• K•••••
Founder or executiveCo-Founder, SpyGlass Pharma
M••• L•••••
Founder or executiveCEO, GT Medical Technologies
M•••••• A••••••••
Founder or executiveCEO, Presidio Medical
N•••• Y••••
Founder or executiveCEO, CVRx
P••• S•••••••••
Founder or executiveCEO, Enterra Medical
R••• M•••
Founder or executiveChairman, Relievant Medsystems
R•• T•••••
Founder or executivePresident, J&J Biosense Webster
T•• P••••••
Founder or executiveCEO, Cartiva
T••• B•••
Founder or executiveCEO, Metavention
T•• W•••••
Founder or executiveCEO, VS3 Medical
J••••• K••••
Managing partnerCo-founder and Managing Partner
K••• G• N••••••
Managing partnerManaging Partner · since Dec 1, 2018
K••• N••••••
Managing partnerco-founder and Managing Partner
P•••• J••••• K••••
Managing partnerManaging Partner · since Jan 1, 2019
A••••••• S••••
PartnerPartner
B••• B•••••
PartnerManaging Director & Chairman, Versant Ventures
G••• B•••••
PartnerPartner
G••• B•••••
PartnerPartner
M•••• B••••••
PartnerPartner
M••• K•••••
PartnerPartner
S••••• M•••••
PartnerPartner, Knobbe Martens
E•••• E•••••
Platform and operationsExecutive Assistant
K•••••• F••
Platform and operationsExecutive Assistant
M••••• S•••••••
Platform and operationsFund Finance Manager
N••••• N•••••
Platform and operationsExecutive Assistant
S•••• M••••••••
Platform and operationsCFO, Aldevron
S•••• S•••••
Platform and operationsPartner and Chief Financial Officer
S••••• L• P• S•••••
Platform and operationsChief Financial Officer · since Feb 1, 2021
S•••••• O•••••••
PrincipalBoard Director, Baxter
B••• H••••••
Venture partnerVenture Partner
T••••• T•
Venture partnerVenture Partner
Investments on record
1 edges, 1 companies, 1 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| T••• H•••••• I••• | Series A · Series A | lead | G••• B••••• (confirmed) | $30.0M | unknown | Jul 21, 2026 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
2 relationships from shared deals, counted for the whole firm
Limited partners
1 disclosed
Timeline
7 dated events
- Mar 31, 2026SDCERS reports V•••••• Capital I, L.P.: $3,000,000 committed, vintage 2018, net IRR 17.9%, 1.65x
- Mar 8, 2022V•••••• C•••••• I•• L••• first reported on Form ADV by V•••••• C•••••• M••••••••• L•• (Venture Capital Fund), GAV $325,000,000Fund first reported on Form ADVFundsFactV•••••• C•••••• I•• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Feb 1, 2021S••••• L• P• S••••• joined Schedule A of V•••••• C•••••• M••••••••• L•• as Chief Financial Officer
- Feb 8, 2019VMT Management, LLC first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Feb 8, 2019V•• F••• I• L••• first reported on Form ADV by VMT Management, LLC (Venture Capital Fund), GAV $167,764,677Fund first reported on Form ADVFundsFactV•• F••• I• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Dec 13, 2018V•• F••• I• L••• filed Form D/A: no sales yet of $200,000,000, Venture Capital Fund
- Dec 10, 2018V•• F••• I• L••• filed Form D: no sales yet of $200,000,000, Venture Capital Fund
Classification history
- Sep 15, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $586M across 4 vehicles
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $586M across 3 vehicles
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $586M across 2 vehicles
Evidence
79 observations from 4 sources